JCP
AGIO icon

Jabre Capital Partners’s Agios Pharmaceuticals AGIO Stock Holding History

Jabre Capital Partners’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-5,200
Closed -$438K – 136
2018
Q2 		$438K Sell
5,200
-9,300
-64% -$811K 0.03% 130
2018
Q1 		$1.19M Sell
14,500
-19,500
-57% -$1.51M 0.26% 83
2017
Q4 		$1.94M Buy
+34,000
New +$2.14M 0.4% 71

Other funds holding AGIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return

Jabre Capital Partners's AGIO Position: Q3 2018 in Review

Jabre Capital Partners sold out of Agios Pharmaceuticals (AGIO) in Q3 2018, closing a stake of 5,200 shares — an estimated $438K sold.

Jabre Capital Partners first reported a position in AGIO in Q4 2017 and held it in 3 quarters. The position peaked at $1.94M in Q4 2017. 208 funds tracked by Wall St. Rank hold AGIO as of Q3 2018.

  • Jabre Capital Partners reported no remaining Agios Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Jabre Capital Partners sold 5,200 Agios Pharmaceuticals shares in Q3 2018, an estimated $438K.
  • Jabre Capital Partners first reported a position in Agios Pharmaceuticals in Q4 2017 and held it in 3 quarters.
  • Jabre Capital Partners's Agios Pharmaceuticals position peaked at $1.94M in Q4 2017.
  • 208 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q3 2018.

Based on Jabre Capital Partners's 13F filing for Q3 2018, filed 14 Nov 2018.